Relay Therapeutics heads into its Q1 2026 earnings print today carrying one of the sharpest tensions in small-cap biotech: 16.3% of the free float sold short, yet not a single analyst holds anything other than a buy-equivalent rating.
Short interest is the dominant positioning story here. At 16.3% of float — up 21% over the past month — bears have been adding aggressively as the stock fell 28% from its recent high to close at $12.07. Days to cover run at 8.7, meaning a meaningful short position would take nearly two weeks to unwind at normal volumes. Despite that build, borrowing conditions remain relaxed. Availability is around 702% — roughly seven shares available to borrow for every one already lent — and the cost to borrow is only 0.61%, a fraction of typical squeeze territory. The borrow market is not congested. Short sellers face no mechanical pressure today.
Options traders are not sounding alarms either. The put/call ratio is running at 0.16, only marginally above its 20-day average of 0.14 and nowhere near its 52-week high of 0.55. That is a firmly call-skewed market — options positioning reflects more upside interest than downside protection ahead of the print. The contrast with the short-interest build is notable: the same stock where bears have been adding for four consecutive weeks is also attracting above-average call activity.
The analyst community is unambiguously bullish, and recently more so. Goldman Sachs raised its target from $13 to $22 in late April, maintaining its Buy rating. Raymond James lifted its target to $26 just yesterday, keeping a Strong Buy. Wells Fargo, Barclays, and Oppenheimer all raised targets in the same late-April cluster. The consensus mean target sits at $22.83 against a $12.07 close — implying roughly 89% upside. Bulls point to the Dynamo platform's computational drug discovery edge and promising tolerability data from front-line oncology candidates. Bears counter with the standard clinical-stage risks: binary trial outcomes, regulatory uncertainty, and an equity raise that looks increasingly likely as the cash burn continues — the EV/EBITDA of –6.1x reflects a company spending well ahead of any revenue.
Adage Capital built a 2.09 million share position in Q1, and FMR (Fidelity) added 3.5 million shares by end of April. That institutional buying provides some counterweight to the short-side pressure, though SoftBank's Vision Fund entity — the largest holder at 14.6% — reported flat for the year through December.
Past earnings reactions have been inconsistent. The February 2026 print delivered an 11.3% one-day gain and a further 4.6% over five days. The most recent event in early May produced a 1.3% decline over both time horizons. With a stock down nearly 30% in a month, today's print becomes a direct test of whether the Dynamo platform data can re-anchor analyst conviction in the market's eyes — or whether the persistent short build reflects something the Street's unanimous buy ratings have yet to price in.
See the live data behind this article on ORTEX.
Open RLAY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
